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Abstract
Objective To re-evaluate gonad shielding in paediatric
pelvic radiography in terms of attainable radiation risk
reduction and associated loss of diagnostic information.
Methods A study on patient dose and the quality of gonad
shielding was performed retrospectively using 500 pelvic
radiographs of children from 0 to 15 years old. In a
subsequent study, 195 radiographs without gonad shielding
were included. Patient doses and detriment adjusted risks
for heritable disease and cancer were calculated with and
without gonad shielding.
Results For girls, gonad shields were placed incorrectly in
91% of the radiographs; for boys, in 66%. Without gonad
shielding, the hereditary detriment adjusted risk for girls
ranged between 0.1×10
−6 and 1.3×10
−6 and for boys
between 0.3×10
−6 and 3.9×10
−6, dependent on age. With
shielding, the reduction in hereditary risk for girls was on
average 6±3% of the total risk of the radiograph, for boys
24±6%. Without gonad shielding, the effective dose ranged
from 0.008 to 0.098 mSv.
Conclusions With modern optimised X-ray systems, the
reduction of the detriment adjusted risk by gonad shielding
is negligibly small. Given the potential consequences of
loss of diagnostic information, of retakes, and of shielding
of automatic exposure-control chambers, gonad shielding
might better be discontinued.
Keywords Radiography.Paediatric.Pelvis.Gonads.
Radiation risk
Introduction
Protection of the gonads against diagnostic X-rays gained
ground in the 1950s [1–4]. Among the reasons were the
increased radiation awareness caused by the genetic effects
observed in irradiated fruit flies and the higher cancer
incidence in the atomic bomb survivors. Both effects are
supposed to be induced without a threshold dose [5, 6].
Gonad shielding in radiology has become common
practice and is recommended by national and international
bodies [7, 8]. The conditions for its application given in [8]
are: “(a) The gonads will lie in the primary X-ray field or
within close proximity (5 cm); (b) the clinical objectives of
the examination will not be compromised; (c) the patient
has a reasonable reproductive potential”.
Gonad shielding may be quite effective as it can lower
the dose to the testes by about 95% and the dose to the
ovaries by about 50% [7]. The lower level of protection in
females is mainly due to the large spread in the position of
the ovaries, including areas far from the midline lying
anterior to pelvic anatomy that has to be visible in the
image [7, 9]. In the early years the attainable dose reduction
was also high in an absolute sense, because the doses
needed for imaging were high. In his 1953 review on the
potential hazards of the use of X-rays in paediatrics, Miller
[6] reported a patient entrance dose of about 12 mGy for a
radiograph, and an entrance dose rate of 100–200 mGy/min
during fluoroscopy. Fluoroscopy at that time was performed
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instead of radiography, easily resulting in entrance doses of
a few hundred mGy. Other investigators [10–12] reported
similar dose values, but efforts to reduce patient dose were
underway [13].
Unfortunately, the use of gonad protection is not only
advantageous, as becomes clear from many evaluations that
show that gonad shielding is poor in daily practice [14–21]. It
appears to be very difficult to place the X-ray shield correctly,
i.e. fully covering the target area but none of the bony pelvic
structures. As a consequence, many images are suboptimal or
worse, leading to loss of diagnostic information that impairs
the radiologist’s work. Moreover, the dose reduction can be
limited as well, or there may even be a dose increase.
Since the introduction of gonad shielding there have
been major advances in X-ray imaging technology and
radiation biology. The improved technology and optimisa-
tion of imaging protocols have resulted in much lower
doses [22–31], while the risk for heritable disease has been
found to be lower than previously assumed [32]. The
question then arises whether today’s reduction in radiation
risk by applying gonad shielding is still worthwhile in view
of its negative consequences. This balance has not been
drawn up so far and as the outcome might have a large
impact on daily practice, we decided to re-evaluate the
benefit of gonad shielding in terms of attainable radiation
risk reduction and associated loss of diagnostic information.
Materials and methods
Optimisation as the incentive for this study
The three pillars of the radiation protection model of the
International Commission on Radiological Protection
(ICRP) are justification, optimisation and dose limits [32].
To comply with the second obligation, optimisation, X-ray
procedures should be re-evaluated from time to time. We
performed such an evaluation of pelvic radiography in
children, using data already available in our Picture
Archiving and Communication System (PACS) (Kodak
Carestream Health, Rochester, NY). Organ and effective
doses, and the effect of gonad shielding on these doses,
were calculated using PCXMC, a Monte Carlo program for
estimating patient doses in medical X-ray examinations
(STUK—Radiation and Nuclear Safety Authority, Helsinki,
Finland). These calculations showed that gonad shielding
(1 mm Pbeq., Dr. Goos-Suprema, Heidelberg, Germany)
gave a trivial reduction of the already very small radiation
risk. At the same time, we often observed a serious loss of
diagnostic information caused by improper gonad shield-
ing. On the basis of these findings the radiological staff
unanimously decided to discontinue gonad shielding in
paediatric pelvic imaging using X-rays. Realising that our
results might be of wider interest and appropriate for
publication, we extended our initial investigation with more
data, obtained both before and after discontinuation of
gonad shielding. This extended study is the subject of this
article; with respect to its execution the Medical Ethics
Committee of the Maastricht University Medical Center
formally acknowledged that no medical ethical approval
was required.
Patients and X-ray projection
In the first retrospective study we investigated gonad
shielding and patient dose in children aged 0–15 years.
The children had a standard anterior-posterior (AP) pelvic
radiograph in 2007 or 2008, mostly in relation to congenital
hip dysplasia. The projection covered the region from the
iliac crests to 2 cm below the trochanter minor on the
femur. Following the majority of other investigators [22–
26, 33, 34], we distinguished age groups of 0–1 years, 1–5
years, 5–10 years and 10–15 years. Additional radiographs
were evaluated in the second retrospective study in 2010
after we had stopped the application of gonad shields.
Image acquisition and storage
Thepelvicradiographshadbeenacquiredinthreerooms,each
equipped with an X-ray system using a digital flat panel
detector (AXIOM Aristos FX Plus; Siemens, Erlangen,
Germany). These systems have pre-programmed protocols,
which set the high voltage (kVP), additional filter, focus to
image-detector distance, and either a fixed tube current-
exposure time product (mAs value) or the automatic
exposure control (AEC). The protocol indicates whether the
bucky anti-scatter grid has to be present or absent, but grid
insertion or removal has to be done manually. We have no
special team of technicians for paediatric radiology within
our department.
For the younger patients, age-dependent protocols with
fixed technique parameters are used. For the 10–15 age
group different protocols are applied because the children
of this age vary strongly in size. For the smaller patients no
grid and no AEC are used, for the group of more adult sized
patients they often are.
After acquisition, the images are “shuttered”,i . e .
irrelevant edges of the images are removed digitally.
Subsequently the images are sent to our PACS in Digital
Imaging and Communications in Medicine (DICOM)
format. The DICOM header contains retrievable informa-
tion on the exposure [e.g. kVP, filter, mAs value, use of the
grid and the air kerma-area product (KAP)]. Information on
the use of the AEC is not stored, neither is the size of the
unshuttered field of view.
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Because the quality of gonad shielding potentially has a
large impact on the diagnostic information in the image and
the dose reduction as well, the shielding was visually
evaluated (by M.J.F.). For boys, the gonad shield had to
fully cover the testes, while all bony pelvic parts remained
uncovered. For girls, the central section ofthe pelvis had to be
covered, again without shielding parts of the pelvic bones,
with the exception of the sacrum to just below the sacro-iliac
joints.Theradiographmadeduringthepatient’sveryfirstvisit
to the department was obtained without shielding.
Judging from the presence of poor images, retakes had
been limited to the absolute minimum. In the evaluation, we
therefore identified also all images in which important
diagnostic landmarks were not visible due to shielding.
Specifically we considered assessability of Shenton’s line,
Perkin’s lines and the acetabularangle (see Fawcett etal. [20],
their Fig. 3); these studies were labelled as “retake required”,
although no retake was obtained in reality. Unfortunately, the
real number of retakes could not be determined.
Wealsoestimatedthefractionofthetestesthatwasactually
shielded (percent coverage) by visual inspection of the
radiographs. The corresponding testes dose reduction was
calculated with PCXMC as the dose to the testes due to
an exposure with the size of the gonad shield, with the
field overlaying “percent coverage” of the testes in the
cranial-caudal direction. For girls, we assumed that
protection is not very sensitive to positioning of the shield
(in a statistical sense at least), because of the large spread
in the position of the ovaries [9].
Determination of patient dose
In the first dosimetric study (data from 2007 and 2008)
gonad shielding was standard, in the second study (data
from 2010) shielding was absent.
Together with the discontinuation of the gonad shielding,
we continued to optimise our protocols. In the first place,
more guidance for the imaging of larger children (10–
15 years) was introduced because of large differences in
exposure within this group. Secondly, following the
European Guidelines [35], we added an additional copper
filter of 0.1 mm for the two intermediate age groups. For the
youngest patients (0–1 years) the decrease in image quality
was considered too large by the paediatric radiologist; for the
10–15 age group, the filter was already used.
The basic filtration of the X-ray beam (i.e. in the absence
of 0.1 mm Cu) was determined from the measured half-
value layer in aluminium. Since most authors had reported
the entrance dose as a dose-in-air including backscatter [22,
23, 25–31], we followed this convention. We estimated
backscatter factors for the conversion of incident air kerma to
entrance dose for each age group and radiation quality using
data from the NRPB report R279 [36]. These factors were
1.26, 1.35, 1.39, 1.45 and 1.48 for the age groups 0–1y e a r s ,
1–5 years, 5–10 years, 10–15 years small childen and
10–15 years large children, respectively. The incident air
kerma was derived by PCXMC from the KAP and the
estimated unshuttered image size. Note that the dose in tissue,
usedintwopublications[24, 33], is about 5% higher than the
entrance dose as used by most other investigators and us.
Input information for PCXMC comprises imaging
technique settings (kVp, filtration), KAP, image field size
and projection. Note that these exposure parameters are
generally independent of the use of gonad shielding, unless
the shield was in front of an active AEC chamber. The
effect of shielding is taken into account by subtracting a
fraction of the gonad dose calculated for the no-shield
exposure; under optimal circumstances this subtracted
fraction amounts to 95% in male patients and 50% in
female patients [7].
PCXMC has the option to adjust the size of the
phantoms of all ages. The dose estimation in a specific
age group of children will be illustrated using the 5–10 age
group as an example. Rather than treating these children as
a single group in the dose calculation, we considered 5- to
7.5-year-olds and 7.5- to 10-year-olds separately to reduce
the potential effects of spread in patient size. By interpo-
lation between data for child phantoms of different age
present in PCXMC, we determined the weight and length
of children of 6.25 and 8.75 years. Using the exposure
parameters and interpolated patient size and weight for each
subgroup, organ doses and effective dose were calculated
with PCXMC for the 6.25- and 8.75-year-olds. The average
dose for the 5–10 age group was then calculated by
averaging the results for these two subgroups. Doses for
other age groups were estimated in a similar fashion
(always using two subgroups).
The problem of the collimator settings not being stored in
the DICOM header (necessary as input on field size) was
addressed by determining the average difference in width and
height of the original (unshuttered) and shuttered images for a
limited set of images for which both types of data were
retained. Considerable variations in measured differences
existed, but on average 1 cm had to be added in all four
directions to compensate for the shuttering. Although this
correction for shuttering is necessarily approximate, its
application was preferred over leaving it out as this system-
atically would overestimate the entrance dose. To derive the
effective dose from organ doses, the tissue-weighting factors
published in ICRP 103 were chosen in PCXMC.
As gonad shielding is applied to limit hereditary effects,
the detriment adjusted risk for heritable disease was
estimated (the ‘detriment adjusted risk’ takes the various
potential, negative consequences of the exposure into
Insights Imaging (2012) 3:23–32 25account, weighting for the seriousness of the corresponding
harms; for the official definition see ICRP 103 [32]).
Cost-benefit calculation
Because we saw no solution to the problem of translating
the loss of diagnostic information into a numerical risk that
might be compared with the risk of radiation, we limited the
quantitative risk analysis to radiation effects only.
Shortcomings of gonad shielding, which manifest them-
selves inevitably in daily practice, and which have an impact
on the patient dose, are: (1) in males, an incomplete coverage
of the testes, (2) the need for retakes because vital landmarks
are obscured and (3) an increase in dose when an active AEC-
chamber is(partly)shielded bythe leadsupposed toshieldthe
gonads. Only point 1 was taken into account, the other two
were not, because of missing information.
The detriment adjusted hereditary risk of a pelvic radiograph
can be calculated using the nominal coefficient of 5.4 × 10
-3 Sv
-1
for persons of reproductive age [32]. For the computation of
the total detriment adjusted risk, the risk coefficient for cancer
(5.5 × 10
-2 Sv
-1 for the whole population [32]) with an age-
dependent correction for the higher cancer risk for children [37]
is needed as well. These calculations further require the
effective dose, the testes dose and the dose to the ovaries.
The reduction of hereditary risk achieved by gonad shielding
was also expressed as a percentage of the total risk of a
radiograph obtained without shielding.
Results
Gonad protection
In total, 500 AP pelvic radiographs with gonad protection were
identified in the period 2007–2008. By keeping very strictly to
the criteria for good diagnostic information, our scores for
gonad protection left much to be desired (Table 1). For girls, in
91% the shielding was not applied strictly according to the
rules; for boys, in 66%. In one case a poorly positioned shield
covered an osteomyelitic lesion in a boy (Fig. 1). Rates of
retakes that would be required if all essential landmarks had to
be visible are also shown in Table 1.
Over the whole range of 0-100% coverage of the testes,
the average dose reduction decreased with increasing age
(and kVp) from approximately 0.98 to 0.90 times the
coverage. So for practical purposes, the fractional testes
dose reduction is equal to the fractional coverage. The
actual reduction in testes dose, taking this partial shielding
into account, is for boys of 0–1 years 51%, 1–5 years 54%,
5–10 years 76% and 10–15 years 77%. For girls, the
literature value of 50% was assumed as explained above.
Table 1 Summary of gonad shielding during paediatric AP pelvic radiography in the period 2007-2008
Age Male (n
a=193) Female (n
a=307 )
(years) n
a Shielding incorrect
b (%) Retakes required
c (%) n
a Shielding incorrect
b (%) Retakes required
c (%)
0-1 14 64 7 92 97 58
1-5 40 52 0 113 87 28
5-10 87 71 1 50 90 0
10-15 52 69 0 52 88 0
aNumber of radiographs
bShielding strictly according to standard rules (see text)
cBecause an important anatomical landmark was obscured, but retake was not actually taken
Fig. 1 Conventional pelvic
radiograph with testes shielding
(left). An osteomyelytic lesion is
clearly displayed (arrow)
(right). Due to gonad shielding
this was missed in the previous
examination
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The 2010 study included 195 AP pelvic radiographs
acquired without gonad shielding. The imaging technique
settings used are shown in Table 2; part of these data were
necessary in the dose calculations. The basic filtration of the
X-ray beam was 3.3 mm Al. Table 3 presents the KAP, the
incident air kerma, the effective dose (for a hermaphrodite),
the gonad doses and the contribution of the gonads to the
effective dose. Due to the absence of the Cu filter for the
group of children of 0–1 years their dose is higher than that
for the 1–5 age group. Note the relative spread in all doses in
Table 3 will be a little higher than specified for the KAP due
to the additional uncertainty in the X-ray beam area. The
dose data from the 2007–2008 study were only slightly
higher and are not shown.
Cost-benefit calculation
Table 4 gives for the different age groups an overview of
the total and hereditary detriment-adjusted risks caused by
pelvic radiographs. Note the very low absolute magnitude
of risks for boys and girls alike. For boys, there was an
average reduction of the risk of heritable disease as
percentage of the total risk of 24±6% when shielding was
used; for girls, 6±3%. Assuming uncompromised protec-
tion of the gonads (according to ICRP 34, 95% gonad dose
reduction in boys, 50% in girls [7]), without any dose
increase by collateral effects, this reduction would be 33±
5% in boys and 6±3% in girls. Taking the retakes into
account that would be required according to the rules for
properly shielded images, the total risk reduction for boys
would hardly change (23±8%) with respect to not using a
gonad shield, but for girls there would be an increase in
total risk of 10±27%.
Discussion
The absolute magnitude of the reduction in hereditary risk,
even assuming complete uncompromised shielding of the
gonads, was very small. Several factors are responsible for
this finding. First of all, technical developments and
protocol optimisation have lowered the dose needed for a
Table 3 Mean dose data AP pelvic radiography in absence of gonad shielding (n=195)
Age KAP
a Incident air
kerma
Effective dose
ICRP 103
Organ dose
testicles
Organ dose
ovaries
Contribution of gonads
to effective dose
(years) (mGy·cm
2)( μGy) (μSv) (μGy) (μGy) (μSv)
0-1 18.8±7.8 87 13 97 20 5
1-5 16.6±6.3 46 8 56 14 3
5-10 49±28 84 15 111 24 5
10-15
b 168±125 223 40 319 98 17
10-15
c 369±156 484 98 725 249 39
aAir kerma-area product
bSmaller children, typically no grid and no AEC
cLarger children, typically with grid and/or AEC
Table 2 Imaging technique settings in AP pelvic radiography
a
Age n Filter
b High voltage mAs value
c AEC Grid
(years) (mm Cu) (kV) (mAs) (yes/no) (yes/no)
0-1 36 - 50 4.2 n n
1-5 63 0.1 55 5.2 n n
5-10 43 0.1 55/60 6.5 n n
10-15
d 27 0.1 70 12 y/n y/n
10-15
e 26 0.1 81 13 y y
aThe average focus-image receptor distance was 117±24 cm
bInherent filtration was 3.3 mm Al-equivalent
cTube current exposure time product
dSmaller children, typically no grid and no AEC
eLarger children, typically with grid and/or AEC
Insights Imaging (2012) 3:23–32 27pelvic radiograph from about 10 mGy in the 1950s to a few
tenths of a milligray today. Secondly, the risk coefficient for
heritable disease is considerably lower than previously
assessed.
For about 50 years, radiographers worldwide have been
applying gonad shielding in radiography of the pelvis and
abdomen. All available studies, including our own, show
that gonad shielding is poor in clinical practice (Table 5).
Impaired diagnostic information and limited gonad dose
reduction are potential consequences. In unfortunate cases
there can even be an increase in exposure due to the need
for retakes or due to shielding an active AEC chamber,
effects that could not be quantitatively included in this
study due to the lack of adequate information. The risk
reductions we calculated are thus likely to be too optimistic.
The patient doses incurred in our department are
relatively low, but not exceptionally, as can be seen in
Table 6, which presents data published in the past 20 years
[22–30, 33, 34]. We identified more than 40 articles with
pertinent data, but only studies giving doses for children of
several ages were included. Note that the dose to a
superficially located organ like the testis will be similar to
the entrance dose.
Table 6 also shows considerable spread in doses.
Thirteen out of 15 reported entrance doses for 0 to
1-year-old children are lower than the diagnostic reference
level (DRL) of 640 μGy given in the European Guidelines
[35] for 4-month old infants, while 12 out of 15 values for
1 to 5-year-old children are below the DRL of 924 μGy for
5-year-olds. Smans et al. [31] reported data from a
European survey that do not fit in Table 6 due to a different
age grouping. Their doses include a low median value of 48
μGy for children younger than 1 year and quite a high
mean value of 3,460±2,730 μGy for 8 to 12-year-olds. The
large spread and the many high values reported in the
literature indicate that a lot is still to be gained by
optimisation. This issue is currently being addressed in
many countries by setting DRLs for frequently performed
procedures, as recommended by the ICRP [32, 38].
Discontinuation of gonad protection should not be consid-
ered before optimisation has been performed and dose
levels in the low range of Table 6 have been realised.
Table 5 Gonad shield positioning in pelvic radiography according to various studies
Ref. Number of radiographs with shielding Percentage with incorrectly placed shields
Boys Girls Total Boys Girls Average
a
(%) (%) (%)
Kenny and Hill [14] 102 107 209 44 60 52
Wainwright [15] 76 40 116 38 59 45
McCarty et al. [16] 82 57 139 63 72 67
Sikand et al. [17] 110 26
Gul et al. [18] 678 31
Masud et al. [19] 100 78
Fawcett and Barter[20] 611 550 1161 26 48 36
McManus and Davis [21] 618 741 1359 59 71 66
This study 193 307 500 66 91 81
aTaking the number of each sex into account
Table 4 Detriment adjusted risks caused by AP pelvic radiography with and without gonad shielding
Age Total risk without shielding Hereditary risk without shielding Hereditary risk with shielding
Boys Girls Boys Girls Boys Girls
(years) per 10
6 per 10
6 per 10
6 per 10
6 per 10
6 per 10
6
0-1 1.6 1.3 0.5 0.1 0.2 0.1
1-5 1.0 0.8 0.3 0.1 0.1 0.0
5-10 2.0 1.6 0.6 0.1 0.1 0.1
10-15
a 4.2 2.7 1.7 0.5 0.4 0.3
10-15
b 10.2 6.8 3.9 1.3 0.9 0.7
aSmaller children, typically no grid and no AEC
bLarger children, typically with grid and AEC
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Insights Imaging (2012) 3:23–32 29Installation of a modern digital system is no guarantee for
acceptable performance.
Patient dose reductions since the fifties were realised by
using harder radiation, a larger focus-patient distance, the
introduction of faster screens and films, and the discontin-
uation of fluoroscopy in favour of radiography. In fluoros-
copy the introduction of the image intensifier was a major
step. Recently the more sensitive digital detectors and the
concomitant development of image processing software
helped reduce patient dose.
Despite its limitations, gonad shielding has served its
purpose in times when doses were high. Now it appears that
its potential advantages are outweighed by the drawbacks.
Too many images contain impaired diagnostic information.
The high numbers of retakes required, but not actually taken,
are symptomatic. Often the radiologist is forced to fill in the
gaps with information from previous images. This is not
without risk, as illustrated by the incident with the shielded
osteomyelytic lesion ( Fig. 1). This incident shows that even
the peripheral zones of pelvic bones should not be covered.
The uncertainties in the derived doses still need to be
considered. The KAP meters are calibrated on a regular
basis and their accuracy is typically within 5-10%. PCXMC
has only a limited number of mathematical phantoms, and
the size of the individual patient may not correspond to that
of the phantom closest in age. As a consequence, in some
cases PCXMC’s dose estimates will be too high, and in
others too low, but the average dose estimate for patients
within an age group will be fairly realistic. The correction
for shuttering to obtain the true X-ray field size introduces
an additional uncertainty in the dose estimates. To give an
idea of its magnitude, assume that the uncertainty equals
the fully applied correction of 1 cm in all directions. This
would result in an uncertainty of the estimated area of
±13% for the smallest and ±6% of the largest fields. Note
that for a given KAP the effect of a change in the beam area
on the effective dose is likely to be small, but on the dose to
the gonads (or any other single organ) it will have its full
impact. Taking all considerations together, the accuracy of
the average calculated dose should be better than about
20%. For individual patients the error may be larger, as
indicated by the spread in KAP values in Table 3.
An important practical aspect for this discussion is the
perception of radiation risks. The emphasis over the years
on applying gonad shields has nurtured the conviction that
major risks have to be countered. Workers and parents are
so used to shielding that not using it is considered a major
neglect. And it cannot be denied that there is an average
risk reduction for boys of about 24% and of 6% for girls, so
why stop protection? The answer is given by the ICRP,
which advises that risks in the range 10
−6-10
-7 be
considered as of no concern [39]. Only for the group of
large boys of age 10–15 years is the potential reduction in
hereditary (or total) risk 3.0 × 10
−6.
Radiographers should learn that the risks associated with
the potential loss of diagnostic information outweigh the
very small benefit of gonad shielding. Parents could be
helped by showing them the risks of exposures that are
commonly accepted as harmless. A few have been collected
in Table 7 and they illustrate how small the effective dose
(which also accounts for the gonad dose) of pelvic
radiography in children is. The NCRP considers 10 μSv
as a negligible annual effective dose [40]. As a final
example of the risk of a normal life activity, a drive by car
over 100 km, e.g. for a retake of the image in Fig. 1, has in
the EU on average a risk of 1 × 10
−6 for a fatal accident
[41], the risk for an injury is much higher.
Conclusion
There are good arguments to stop gonad protection in
pelvic radiography of children, provided modern equipment
and properly optimised imaging protocols are used. The
risk reduction for girls and young boys is marginal, for
older boys there is room for discussion. Our staff decided
upon images of constant good quality, for all children,
rather than the minor benefit of gonad protection. Available
resources for education and optimisation are better directed
at applications with a potentially higher risk reduction.
Table 7 The effect of a few
trivial activities in all-day life on
effective dose
a
aApproximate data, exact values
depend on several details
Action Saving Expense
Lowering radon (
222Rn) concentration at home with 1 Bq/m
3 [42]
(e.g. by increasing ventilation; worldwide average conc. 40 Bq/m
3)8 0 μSv/year
Holidays on a cruise ship instead of on land [43]2 μSv/day
Large distance flying [44]5 μSv/h
Visit of cave with relatively low radon concentration of 1 kBq/m
3 [45]4 μSv/h
Person living in Cornwall (6.5 mSv/year due to radon only) going
to London (1 mSv/year) [46]1 5 μSv/day
Living in The Netherlands (2 mSv/year) 5 μSv/day
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